Asieris Pharma Raises over ￥100M in Series C Round

According to dealstreetasia.com, Asieris Pharmaceuticals ("Asieris"), which is focused on genito-urinary tumor treatments, has raised over 100 million yuan (US$14 million) as part of its Series C round of financing led by Yanyuan Innovation Capital, according to a company statement recently. State-owned Shenzhen Guozhong Venture Capital Management, biomedicine based investment firm Efund Capital, existing investors Lapam Capital and Kaitai Capital also joined the round.

Asieris will use the proceeds to further facilitate its proprietary biomedicine programmes. It is expected to close its Series C+ round funding soon.

Prior to the current round, the company had raised funding from lifesciences-focused venture capital firm TF Capital, private equity firm Phoenix Fund, ZGC Group-backed Qihang Capital, among others. 

Founded in 2013 and located in East China's Jiangsu province, Asieris is a global innovative drug research and development company focusing on tumors of the urogenital system and related diseases.

Asieris's pipeline APL-1202 is under phase III clinical trials in China and phase II trials in the US. APL-1202 is the world's first kind of drugs of non-muscular invasive bladder cancer entering into clinical trials. As an oral drug with the innovative anti-tumor mechanism, the whole treatment using APL-1202 is convenient, painless and has no damage to the urethra, which will help patients avoid or delay the total bladder resection.

APL-1702 (Cevira^®) is a photodynamic drug-device combination product. It consists of a convenient, fully integrated drug delivery and the light device which is being developed for non-surgical treatment of high-grade cervical dysplasia.  Asieris will also conduct phase III trials in China, the US, and Europe in 2020.

Headquartered in Taizhou, Asieris has set up divisions in Beijing and the US and an R&D center in Shanghai. 

Founded in June 2010 and headquartered in Beijing, Yanyuan Capital is a venture capital and fund management firm engaged in equity investment, securities investment, and merger&acquisition. The AUM of Yanyuan Innovation Capital is over 6 billion yuan. It mainly invests in biomedicine, advanced manufacturing and new-generation information technology.

Guozhong Venture Capital was founded on the 21st of December 2015, currently being entrusted to manage the first entity fund of Small Medium Enterprises Development Fund（SHENZHEN）LLP with a size of 6 Billion Yuan.

Guozhong Venture Capital has a registered size of 100million yuan, partners consisting of Shenzhen venture capital group (49%) and the management team of Small Medium Enterprise Development Fund (SHENZHEN) (51%).